

OFFICE
MAY 05 2003
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231 on the date shown below

Dated April 29, 2003

Signature _____
Nabeela R. McMillian

Docket No.: 01017/35136
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Zsebo *et al.*

Application No.: 09/224,683

Group Art Unit: 1647

Filed: December 31, 1998

Examiner: Bridget Bunner

For: STEM CELL FACTOR: COMPOSITION
CLAIMS

AMENDMENT UNDER 37 CFR §1.111 IN RESPONSE TO OFFICE ACTION
DATED NOVEMBER 29, 2002

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

MAY 07 2003

TECH CENTER 1600/2900

Dear Sir:

This paper is filed in response to a **non-final** Office Action mailed on November 29, 2002 (Paper No. 16) and is due on **April 29, 2003**, by virtue of the attached petition and fee for a two-month extension of time to respond. No additional fees are believed to be due, however, should any additional fees be deemed necessary in connection with the filing of these documents the Commissioner is hereby authorized to deduct such fees from Marshall Gerstein and Borun account number 13-2855.

In the Claims

71. (Currently amended) A composition which comprises a therapeutically effective amount of an isolated stem cell factor (SCF) polypeptide, or a biologically active SCF fragment or analog thereof comprising at least 130 contiguous amino acids of any of sequences set forth in SEQ ID NO:46, SEQ ID NO:61 or SEQ ID NO:63 that possesses an activity associated with SCF and one or more cytokines in a pharmaceutically acceptable carrier.